An operational perturbation proteomics-based virtual cell model
- Nature. 2026 Oct;658(8137):1066-1076. doi: 10.1038/s41586-026-11001-9.
- 1. Affiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, School of Future Biomedicine, Westlake University, Hangzhou, China.
- 2. Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China.
- 3. Research Center for Industries of the Future, School of Life Sciences, Westlake University, Hangzhou, China.
- 4. DP Technology Co., Ltd, Beijing, China.
- 5. Department of Surgical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
- 6. NHC Key Laboratory of Cell Transplantation, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
- 7. Center for Machine Learning Research, Peking University, Beijing, China.
- 8. Westlake Omics Co., Ltd, Hangzhou, China.
- 9. Department of Big Data and Biomedical AI, College of Future Technology, Peking University, Beijing, China.
- 10. Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
- 11. Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.
- 12. Department of Pathology, School of Basic Medical Sciences, Harbin Medical University, Harbin, China.
- 13. Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, China.
- 14. School of Mathematical Sciences, Peking University, Beijing, China.
- 15. Center for Machine Learning Research, Peking University, Beijing, China. [email protected].
- 16. AI for Science Institute, Beijing, China. [email protected].
- 17. Center for Quantitative Biology, Peking University, Beijing, China. [email protected].
- 18. National Engineering Laboratory for Big Data Analysis and Applications, Beijing, China. [email protected].
- 19. DP Technology Co., Ltd, Beijing, China. [email protected].
- 20. AI for Science Institute, Beijing, China. [email protected].
- 21. Beijing Advanced Center of RNA Biology (BEACON), Peking University, Beijing, China. [email protected].
- 22. State Key Laboratory of Medical Proteomics, Beijing, China. [email protected].
- 23. Affiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, School of Future Biomedicine, Westlake University, Hangzhou, China. [email protected].
- 24. Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China. [email protected].
- 25. Research Center for Industries of the Future, School of Life Sciences, Westlake University, Hangzhou, China. [email protected].
- 26. Affiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, School of Future Biomedicine, Westlake University, Hangzhou, China. [email protected].
- 27. Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China. [email protected].
- 28. Research Center for Industries of the Future, School of Life Sciences, Westlake University, Hangzhou, China. [email protected].
- # Contributed equally.
Artificial intelligence-empowered virtual cell models represent an emerging approach for in silico drug discovery1-3, yet most existing approaches lack large-scale, time-resolved perturbation proteomics data and interpretable frameworks for predicting therapeutic responses. Here we generated more than 38 million temporal protein-abundance measurements from systematically perturbed Breast Cancer cell lines, and developed ProteinTalks, a virtual cell model. Central to ProteinTalks is the synergy of this large-scale dynamic proteomic resource and the model architecture, enabling a new pretraining framework that learns transferable dynamical latent representations from temporal proteome trajectories. By modelling how proteins respond conditionally to different perturbations, this approach enables the model to function as an operational tool for diverse drug discovery tasks: predicting drug efficacy and synergy, discovering new drug combinations, probing proteins associated with drug resistance, stratifying patient responses and prioritizing drug candidates for patient organoids. It also shows robust transferability, extending beyond cell lines to patient-derived organoids and clinical biopsies, generally achieving higher performance than the selected benchmark implementations under the evaluated protocols. Together, ProteinTalks shows how scalable pretraining of transferable dynamic representations enables operational, dynamics-aware, proteomics-based virtual cell models to advance in silico drug discovery.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Topoisomerase; ADC Payloads; AMPK; Autophagy; Apoptosis; HIV; HBV; Mitophagy; Antibiotic; Bacterial; Fluorescent Dye
-
-
-
Research Areas: Cancer
-
-
-
Research Areas: Cancer
-
-
Research Areas: Cancer
-
target: DNA Alkylator/CrosslinkerResearch Areas: Cancer
-
-
-
-
Research Areas: Cancer
-
Research Areas: Cancer
-
-
Research Areas: Cancer
-
-
-
-
-
target: CDK
-
-
Research Areas: Cancer
-
target: Fluorescent DyeResearch Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
-
-
Research Areas: Cancer
-
Research Areas: Cancer
-
target: Reactive Oxygen Species (ROS)
-
-
-
-
Research Areas: Cancer
-
target: Adrenergic Receptor
-
Research Areas: Cancer
-
-
-
-
Research Areas: Cancer
-
-
target: Cytochrome P450Research Areas: Cancer
-
-
-
-
target: CDK
-
Research Areas: Cancer
-
-
target: DNA Alkylator/Crosslinker
-
-
-
-
-
-
Research Areas: Cancer
-